Viatris Soars with 8% Revenue Growth

Viatris just dropped its first-quarter 2026 financial results, and things are looking up! They reported a solid $3.5 billion in revenues, marking an 8% growth compared to last year, with net earnings of $176 million. They also made strides in launching new products like Effexor for anxiety in Japan and expect a hefty cash flow of over $2.5 billion for 2026. What does it mean for you? Viatris is showing they’re on a positive trajectory, which could mean more innovative products and steady supply in the healthcare market, potentially impacting the availability and price of medications you rely on.